Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Sema4
|
| gptkbp:awards |
Best Places to Work.
Innovative Company. |
| gptkbp:ceo |
Randy Scott
|
| gptkbp:collaboration |
Academic institutions.
Biotechnology companies. |
| gptkbp:community_engagement |
Partnerships with non-profits.
Support for cancer research. Health education programs. |
| gptkbp:community_impact |
Improving access to genetic testing.
Raising awareness about hereditary cancers. Supporting women's health initiatives. |
| gptkbp:customer_base |
Patients.
Pharmaceutical companies. Insurance companies. Healthcare providers. |
| gptkbp:financials |
Publicly traded.
NASDAQ: MYGN. |
| gptkbp:focus |
Women's health
|
| gptkbp:founded |
gptkb:2018
|
| gptkbp:founder |
Myriad Genetics.
|
| gptkbp:global_presence |
International markets.
Partnerships in Asia. Partnerships in Europe. |
| gptkbp:headquarters |
gptkb:Salt_Lake_City,_Utah
|
| https://www.w3.org/2000/01/rdf-schema#label |
Myriad Women's Health
|
| gptkbp:industry |
Healthcare
|
| gptkbp:innovation |
Telehealth services.
Artificial intelligence in genomics. Next-generation sequencing. |
| gptkbp:mission |
To improve the lives of women through genetic insights.
|
| gptkbp:number_of_employees |
Over 500.
|
| gptkbp:parent_company |
gptkb:Myriad_Genetics
|
| gptkbp:partnership |
Various healthcare providers
|
| gptkbp:product |
BRACAnalysis
Endo Predict My Risk my Plan |
| gptkbp:regulatory_compliance |
CLIA certified.
FDA approved tests. |
| gptkbp:research_focus |
Personalized medicine.
Cancer genomics. Genetic predisposition to diseases. |
| gptkbp:services |
Risk assessment
Genetic testing Clinical testing |
| gptkbp:subsidiary |
Myriad Genetics.
|
| gptkbp:target_market |
Women at risk for hereditary cancers.
Women undergoing fertility treatment. Women with breast cancer. Women with ovarian cancer. |
| gptkbp:website |
myriad.com
|
| gptkbp:bfsParent |
gptkb:MYGN
|
| gptkbp:bfsLayer |
7
|